Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations
Experts’ conclave to pave holistic approach to cancer management
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
Subscribe To Our Newsletter & Stay Updated
